AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK
http://seekingalpha.com/article/1921841-Chelsea-FDA-Panel-Me…
http://www.medscape.com/viewarticle/791268
Statine haben einen hohen Marktanteil, und wenn man die bessere Veträglichkeit von AMR101 in Betracht zieht, sollte man anehmen, dass sie den Statinen einen Tei ihres Marktes wegnimmt.
"On October 16, 2013, the Company disclosed that the EMDAC had voted 9 to 2 against approval of Vascepa for the ANCHOR Indication citing, among other things, concerns surrounding the mineral oil placebo and the failure of recent cardiovascular outcome trials to demonstrate meaningful cardiovascular benefit from reduction in triglyceride levels. On this news, Amarin shares fell $3.16 per share, or more than 61%, to close at $2.01 on October 17, 2013."
Quelle: http://www.ariva.de/news/...ion-plc-and-Certain-Officers-AMRN-4860034
Und zwar in neutraler Abwägung!